Affiliation:
1. Upstate University Hospital , Syracuse, NY , USA
2. The Mount Sinai Hospital , New York, NY , USA
Abstract
Abstract
Purpose
The combination antiretroviral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a single-tablet, once-daily regimen used in individuals living with HIV; however, its use in the context of renal impairment is uncertain. We report 6 patient cases of BIC/FTC/TAF utilization in individuals with HIV with end-stage renal disease (ESRD) requiring long-term hemodialysis (HD).
Summary
These case reports describe the utilization of BIC/FTC/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.
Conclusion
Utilization of BIC/FTC/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.
Publisher
Oxford University Press (OUP)
Subject
Health Policy,Pharmacology
Reference15 articles.
1. Kidney disease and HIV infection;Wyatt;Top Antivir Med,2017
2. The treatment of HIV-associated nephropathy;Kalayjian;Adv Chronic Kidney Dis,2020
3. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy;Roling;Clin Infect Dis,2006
4. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial;Eron;Lancet HIV,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献